Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-386
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-386 is a fixed-dose triple combination therapy developed by Chong Kun Dang Pharmaceutical for the management of type 2 diabetes mellitus. It integrates three distinct mechanisms of action: lobeglitazone, a thiazolidinedione (TZD) that acts as a selective PPAR-gamma agonist to improve insulin sensitivity; sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system; and metformin, a biguanide that reduces hepatic glucose production. The formulation is designed to provide a convenient single-pill regimen for patients requiring multiple glucose-lowering agents, potentially improving adherence and glycemic control. It was approved by the South Korean Ministry of Food and Drug Safety (MFDS) in 2023, becoming the first triple combination drug in Korea to include a thiazolidinedione.
- Brand names
- Duvie-S
- Other names
- Lobeglitazone + Metformin + SitagliptinDuvie S
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on CKD-386.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-386.